Half-year report · Q2
4078.TEDINET S100UO2I
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Amended by S100V7D8 (2025-02-07).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥41.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥82.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥40.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥917m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥885m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥773m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥7.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥121.2bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥125.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥131.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥44.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥50.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥77.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥75.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥14.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥16.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥14.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥107.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-437.65 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-125.53 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.23 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 62.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥910m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥910m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.2bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥38.4bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥37.6bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥798m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥111m |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥65m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥42.8bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥41.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥910m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥635m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥635m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥36.8bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥36.3bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥498m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥136m |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥144m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥41.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥40.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥635m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 516
| Item | Context | Value | Unit |
|---|---|---|---|
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |